Adragos Pharma
Adragos Pharma is a global Contract Development and Manufacturing Organization (CDMO) committed to providing innovative, high-quality pharmaceutical development and manufacturing services. With a strong focus on customer-centric solutions, sustainability, and advanced technologies, Adragos aims to be a leading player in Europe, Japan, and North America. The company emphasizes end-to-end support, from drug development to commercial manufacturing, leveraging state-of-the-art facilities and digital transformation to meet the evolving needs of the pharmaceutical industry. Recently, Adragos Pharma, in collaboration with the Prange Group, completed the acquisition of the Fresenius Kabi production site in Halden, Norway, a leading sterile pharmaceutical manufacturing unit, expanding its capacity and capabilities in sterile liquid production.
Industries
Nr. of Employees
large (251-1000)
Services
Integrated development services including formulation, analytical development, QbD and regulatory strategy for generics, value‑added medicines and new chemical entities.
Preformulation, formulation design, process development and technology transfer in a GMP‑like R&D environment to facilitate scale‑up.
Method development and validation, chemical analysis, dissolution testing and stability studies performed in GMP‑level analytical laboratories.
Feasibility, preclinical and clinical material production under GMP with project operations and clinical trial supply management.
Commercial scale production of sterile liquids, non‑sterile liquids, semi‑solids, oral solids and suppositories across multiple regional facilities.
Automated aseptic filling, vial/ampoule fill‑and‑finish and visual inspection services with high throughput and qualification support.
Integrated development services including formulation, analytical development, QbD and regulatory strategy for generics, value‑added medicines and new chemical entities.
Preformulation, formulation design, process development and technology transfer in a GMP‑like R&D environment to facilitate scale‑up.
Method development and validation, chemical analysis, dissolution testing and stability studies performed in GMP‑level analytical laboratories.
Feasibility, preclinical and clinical material production under GMP with project operations and clinical trial supply management.
Commercial scale production of sterile liquids, non‑sterile liquids, semi‑solids, oral solids and suppositories across multiple regional facilities.
Automated aseptic filling, vial/ampoule fill‑and‑finish and visual inspection services with high throughput and qualification support.
Expertise Areas
- Clinical trial manufacturing and clinical supply management
- Commercial sterile and non‑sterile manufacturing (including IV/sterile liquids and BFS)
- Formulation and process development with technology transfer
- Analytical development and stability testing
Key Technologies
- Aseptic filling with isolators and RABS
- Automated robotic handling for filling lines
- Blow‑fill‑seal (BFS) technology
- Lyophilization (freeze‑drying)
News & Updates
Adragos will participate in CPHI, exploring latest trends, technologies, and challenges in pharma.
Participation in Bio-Europe 2025 to connect with industry leaders and partners.
Adragos will participate in Swiss Biotech Day, engaging with industry leaders and exploring collaborations.
Adragos showcased innovative pharma solutions at Achema 2024, focusing on small molecule development, supply chain resilience, and sustainability.
Adragos Pharma completed the divestiture of its subsidiary Toride Pharma K.K. to Fuji Seal, Inc., streamlining operations and expanding its network.
Adragos acquired Lamda Laboratories, expanding its pharmaceutical development, regulatory, and supply chain services.
Adragos will participate in CPHI, exploring latest trends, technologies, and challenges in pharma.
Participation in Bio-Europe 2025 to connect with industry leaders and partners.
Adragos will participate in Swiss Biotech Day, engaging with industry leaders and exploring collaborations.
Adragos showcased innovative pharma solutions at Achema 2024, focusing on small molecule development, supply chain resilience, and sustainability.
Adragos Pharma completed the divestiture of its subsidiary Toride Pharma K.K. to Fuji Seal, Inc., streamlining operations and expanding its network.
Adragos acquired Lamda Laboratories, expanding its pharmaceutical development, regulatory, and supply chain services.